RIBOLIFE-B Enters Exclusive Global Licensing Agreement with Madrigal for siRNA Assets

Stock News02-11

RIBOLIFE-B (06938) announced that on February 11, 2026 (after trading hours), the company and its subsidiary Ribocure Pharmaceuticals AB entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for the development of six preclinical small interfering RNA (siRNA) therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). Under the agreement, RIBOLIFE-B has granted Madrigal exclusive global rights to utilize its RiboGalSTAR™ platform and siRNA chemical modification technology to develop, manufacture, and commercialize certain preclinical single-target and dual-target siRNA assets. The group will receive an upfront payment of $60 million and could receive up to $4.4 billion in total upon achieving certain development, regulatory, and commercial milestones, in addition to potential royalties on net sales. As of the announcement date, milestone payments under the agreement are contingent on meeting specific conditions, and the final amount the company may receive remains uncertain. This collaboration will leverage RIBOLIFE-B’s proven liver-targeted RiboGalSTAR™ platform to develop new treatments for MASH, marking a significant milestone in the company’s journey to becoming a globally leading innovative siRNA enterprise. It also accelerates the company’s global development and commercialization strategy, aiming to deliver more targeted and effective therapies for unmet medical needs in MASH patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132391081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 18:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132391081","market":"nz","top_or_hot":-1,"title":"RIBOLIFE-B Enters Exclusive Global Licensing Agreement with Madrigal for siRNA Assets","media":"Stock News","content":"<p>RIBOLIFE-B (06938) announced that on February 11, 2026 (after trading hours), the company and its subsidiary Ribocure Pharmaceuticals AB entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for the development of six preclinical small interfering RNA (siRNA) therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). Under the agreement, RIBOLIFE-B has granted Madrigal exclusive global rights to utilize its RiboGalSTAR™ platform and siRNA chemical modification technology to develop, manufacture, and commercialize certain preclinical single-target and dual-target siRNA assets. The group will receive an upfront payment of $60 million and could receive up to $4.4 billion in total upon achieving certain development, regulatory, and commercial milestones, in addition to potential royalties on net sales. As of the announcement date, milestone payments under the agreement are contingent on meeting specific conditions, and the final amount the company may receive remains uncertain. This collaboration will leverage RIBOLIFE-B’s proven liver-targeted RiboGalSTAR™ platform to develop new treatments for MASH, marking a significant milestone in the company’s journey to becoming a globally leading innovative siRNA enterprise. It also accelerates the company’s global development and commercialization strategy, aiming to deliver more targeted and effective therapies for unmet medical needs in MASH patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B Enters Exclusive Global Licensing Agreement with Madrigal for siRNA Assets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B Enters Exclusive Global Licensing Agreement with Madrigal for siRNA Assets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-11 18:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RIBOLIFE-B (06938) announced that on February 11, 2026 (after trading hours), the company and its subsidiary Ribocure Pharmaceuticals AB entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for the development of six preclinical small interfering RNA (siRNA) therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). Under the agreement, RIBOLIFE-B has granted Madrigal exclusive global rights to utilize its RiboGalSTAR™ platform and siRNA chemical modification technology to develop, manufacture, and commercialize certain preclinical single-target and dual-target siRNA assets. The group will receive an upfront payment of $60 million and could receive up to $4.4 billion in total upon achieving certain development, regulatory, and commercial milestones, in addition to potential royalties on net sales. As of the announcement date, milestone payments under the agreement are contingent on meeting specific conditions, and the final amount the company may receive remains uncertain. This collaboration will leverage RIBOLIFE-B’s proven liver-targeted RiboGalSTAR™ platform to develop new treatments for MASH, marking a significant milestone in the company’s journey to becoming a globally leading innovative siRNA enterprise. It also accelerates the company’s global development and commercialization strategy, aiming to deliver more targeted and effective therapies for unmet medical needs in MASH patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1132391081","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132391081","pubTimestamp":1770804560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"RIBOLIFE-B (06938) announced that on February 11, 2026 (after trading hours), the company and its subsidiary Ribocure Pharmaceuticals AB entered into an exclusive global licensing agreement with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06938":"瑞博生物-B"},"translate_title":"RIBOLIFE-B与Madrigal就siRNA资产达成全球独家许可协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"RIBOLIFE-B (06938) announced that on February 11, 2026 (after trading hours), the company and its subsidiary Ribocure Pharmaceuticals AB entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for the development of six preclinical small interfering RNA (siRNA) therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). Under the agreement, RIBOLIFE-B has granted Madrigal exclusive global rights to utilize its RiboGalSTAR™ platform and siRNA chemical modification technology to develop, manufacture, and commercialize certain preclinical single-target and dual-target siRNA assets. The group will receive an upfront payment of $60 million and could receive up to $4.4 billion in total upon achieving certain development, regulatory, and commercial milestones, in addition to potential royalties on net sales. As of the announcement date, milestone payments under the agreement are contingent on meeting specific conditions, and the final amount the company may receive remains uncertain. This collaboration will leverage RIBOLIFE-B’s proven liver-targeted RiboGalSTAR™ platform to develop new treatments for MASH, marking a significant milestone in the company’s journey to becoming a globally leading innovative siRNA enterprise. It also accelerates the company’s global development and commercialization strategy, aiming to deliver more targeted and effective therapies for unmet medical needs in MASH patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132391081","isCrawlerRequest":true}